



IAP6 Rec'd PCT/PTO 12 MAR 2007

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Jose Luis Castro Pineiro et al

Serial No. : 10/581,291

Case No.: T1650P

Examiner:  
(TBA)

Filed : June 1, 2006

For : TREATMENT FOR ALZHEIMER'S DISEASE AND  
RELATED CONDITIONS

Commissioner for Patents  
Alexandria, Virginia 22313-1450

Sir:

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS**  
**FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE**  
**AND/OR AMINO ACID SEQUENCE DISCLOSURES**

In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures, mailed March 5, 2007 (a copy of which is attached hereto), Applicants note that this application does not disclose any nucleotide and/or amino acid sequences such that 37 CFR 1.827 does not apply. Submission of a Sequence Listing is not appropriate. Any fee deficiencies may be charged to Merck Deposit Account number 13-2755.

Respectfully submitted,


Whereby certify that this correspondence is being  
mailed with the United States Postal Service as  
first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450,  
Alexandria, Virginia 22313-1450, on the date  
appearing below.

By J. Eric Thies Date 8 March 2007  
MERCK & CO., INC.

By J. Eric Thies  
J. Eric Thies  
Reg. No. 35,382  
Attorney for Applicants

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-3904

Date: March 8, 2007



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/581,291	Jose Luis Castro Pineiro	T1650P

INTERNATIONAL APPLICATION NO.

PCT/GB04/05234

I.A. FILING DATE	PRIORITY DATE
12/14/2004	12/18/2003

210  
MERCK AND CO., INC.  
P O BOX 2000  
RAHWAY, NJ 07065-0907

CONFIRMATION NO. 3162

371 FORMALITIES LETTER



\*OC000000022733162\*

PATENT DEPARTMENT

MAR 07 2007

J. ERIC THIES

Date Mailed: 03/05/2007

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.  
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebsc>.

**If you are not using EFS-Web to submit your reply, you must include a copy of this notice.**

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/581,291	PCT/GB04/05234	T1650P

FORM PCT/DO/EO/922 (371 Formalities Notice)